国产成人mv免费视频_无码精品毛片波多野吉衣_在线毛片äV网站免费观看_成人亚洲av电影_亚洲爆乳成av人在线网站_中国熟妇乱子hdsex粗_国产无遮挡污在线观看免费Aⅴ_日韩经典精品无码一区18_欧美巨大另类极品ⅴideosbest_午夜成人免费看在线观看

<noscript id="mwyac"><optgroup id="mwyac"></optgroup></noscript>

科學(xué)研發(fā)

科研創(chuàng)新

研發(fā)管線

科研壁報(bào)

同行評(píng)審出版物

投資者關(guān)系

投資者信息中心

企業(yè)管治

財(cái)務(wù)報(bào)告

公告與通函

投資者演示文稿

投資者關(guān)系聯(lián)系方式

投資者關(guān)系日歷

發(fā)布公司通訊

視頻專區(qū)

關(guān)于華領(lǐng)

公司簡(jiǎn)介

發(fā)展歷程

管理團(tuán)隊(duì)

戰(zhàn)略顧問委員會(huì)

高級(jí)科學(xué)顧問委員會(huì)

企業(yè)文化

聯(lián)系我們

科學(xué)研發(fā)

> 科學(xué)研發(fā)

> 同行評(píng)審出版物

科研創(chuàng)新

研發(fā)管線

科研壁報(bào)

同行評(píng)審出版物

同行評(píng)審出版物

Diabetes, Obesity and Metabolism

Diabetes remission in drug-na?ve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

Diabetes Therapy

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

Nature Communications

2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

Nature Medicine

2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin in drug-na?ve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Clinical and Translational Science

2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Global Journal of Obesity, Diabetes and Metabolic Syndrome

2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

Diabetes, Obesity and Metabolism

2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

Clinical Pharmacokinetics

2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Lancet Diabetes Endocrinology

2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

Lancet Diabetes Endocrinology

2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Journal of Diabetes Research

2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

藥學(xué)進(jìn)展

2016年第3期《藥學(xué)進(jìn)展》：葡萄糖激酶激活劑研究進(jìn)展

藥學(xué)進(jìn)展

2016年第3期《藥學(xué)進(jìn)展》：21世紀(jì)2型糖尿病新藥研發(fā)策略：明鑒病理因素，改善機(jī)體功能

Drug Design, Development and Therapy

2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

Intractable & Rare Diseases Research

2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ? Turning challenges into opportunities

Clinical Pharmacokinetics

2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

Intractable & Rare Diseases Research

2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

關(guān)注我們

Copyright ? 2024 華領(lǐng)醫(yī)藥技術(shù)（上海）有限公司互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào): （滬）-非經(jīng)營(yíng)-2022-0079
滬ICP備14036654號(hào)-1

滬公網(wǎng)安備 31011502013809號(hào) 隱私聲明使用條款

搜索

我們?nèi)绾问褂肅ookies

華領(lǐng)醫(yī)藥使用 Cookie 來(lái)改進(jìn)網(wǎng)站的使用。繼續(xù)使用本網(wǎng)站即表示您同意使用這些 Cookie。如需了解更多關(guān)于 Cookie 的信息，請(qǐng)閱讀我們的隱私聲明。

全部接受

x

<samp id="sokku"><tfoot id="sokku"></tfoot></samp><th id="sokku"></th>